Global Bronchoscope Market - 2022-2029

Market Overview

Bronchoscope Market size was valued at US$ XX million in 2021 and is expected to reach US$ XX million by 2029, growing at a CAGR of 6.4% during the forecast period (2022-2029).

A bronchoscope is a class of endoscopes consisting of a flexible, thin, lighted tube incorporated via the nose, mouth, or other access points to the lower airways to allow healthcare professionals to inspect a patient's throat, trachea, larynx, and lower airways. A bronchoscope is used to diagnose irregularities in the airway, the lungs, or lymph nodes in the chest or to treat problems, including an object or change in the airway.

Market Dynamics

The global bronchoscope market growth is driven by increasingly geriatric population, technological advancements, a rising prevalence of respiratory diseases, rising patient awareness, and rising healthcare expenditure.

An increasing prevalence of lung cancer drives the market growth

The increasing number of infectious diseases, such as lung cancer and pneumonia and technological advancements in bronchoscopes drive the market worldwide. Bronchoscopy has several major diagnostic and therapeutic applications in pulmonology. As per the WHO data (2020), cancer is the main cause of death globally, accounting for approximately 10 million deaths in 2020. The most common 2020 new lung cancer cases were 2.21 million cases.

Bronchoscopy delivers unique access to the airways and mediastinum and is continually employed in diagnosing, staging and palliating lung cancer. Tools and techniques in bronchoscopy have advanced significantly in recent years, with improvement in navigation adding to its diagnostic and therapeutic potential. Over the past decade, there has been rising experience with endobronchial intratumoral chemotherapy, which supports its potential use as part of a multi-modality approach to malignant airway obstruction. Further, local delivery provides the most effective delivery route for several immunotherapies under development, such as oncolytic viruses.

Moreover, the market players are adopting the market strategies such as acquisition and product launches to expand their business. For instance, in December 2020, Olympus Corporation acquired Veran Medical Technologies, Inc., a leading advanced medical devices provider specializing in interventional pulmonology. This acquisition helped the company to expand its pulmonary portfolio.

The side effects associated with bronchoscopy will hamper the growth of the market

However, all medical procedures have some side effects. In Bronscopy, the adverse effects include infection, bleeding, hole in the airway (bronchial perforation), irritation in the airway (bronchospasm), irritation of vocal cords (laryngospasm), and air in space between the lung covering (Pleural Space) that that provokes the lung to collapse (pneumothorax). These adverse effects limit the market growth.

COVID-19 Impact Analysis

The COVID-19 pandemic has considerably effects on the broncoscopes market. As per the article published in Critical Care Explorations in September 2021, conducting bronchoscopy in patients with COVID-19 is not without potential risks; this includes possible SARS-CoV-2 transmission to the bronchoscopist and other involved healthcare workers. Another procedural problem is the possibility of clinical deterioration in the periprocedural period, such as precipitation of respiratory failure, the necessity for mechanical ventilation, increased hospital length of stay, or even improved mortality, especially in critically ill patients.

Contrarily, bronchoscopy could be beneficial. Identifying SARS-CoV-2 from the lower respiratory tract may accurately diagnose patients with COVID-19 who had an initial false-negative test. Also, an early diagnosis of a secondary bacterial or fungal infection is essential, as a misdiagnosis can negatively affect patient outcomes. Furthermore, bronchoscopy allows the operator to perform therapeutic interventions that can be lifesaving.

In addition, mechanically ventilated patients with COVID-19 are prone to develop ventilator-associated pneumonia (VAP), which could be unrecognized because of its clinical and radiographic similarity to COVID-19. VAP has an incidence ranging from 29% to 80% in these patients, with a hazard ratio of 2.1 compared to that in non-COVID-19 patients. Such high incidence may be due to several factors, such as prolonged mechanical ventilation or sedationand treatment-associated immune impairment. In those cases, bronchoscopy helps in providing correct diagnosis.

Segment Analysis

The flexible segment is expected to grow at the fastest CAGR during the forecast period (2022-2029)

The flexible bronchoscope segment accounts for the highest market share. As per the article published in Diagnostics journal in September 2021, Flexible bronchoscopy is more widely utilized due to its less invasiveness, deeper capability for exploration of the bronchial tree, and more rapid learning curve; its ancillary techniques permit sampling to be taken from lung and mediastinum, such as broncho-alveolar lavage, trans-bronchial needle aspiration, protected-specimen brush, and trans-bronchial lung biopsy. The insertion of a flexible bronchoscope into endotracheal intubation is of help for reaching the bronchial tree and is more effective in controlling massive bleeding.

In addition, market players produce single-use bronchoscopes, with some currently on fourth-generation devices that have enhanced image quality and degrees of angulation. The range of devices includes a selection of channel diameters. Each company has produced a small portable, reusable screen that is easy to clean and from which videos or images can easily be saved or downloaded. The advantages and easy-to-use of flexible bronchoscopes drive the market worldwide.

Geographical Analysis

North America region holds the largest market share of the global bronchoscope market

North America dominates the market for bronchoscopes and is expected to show a similar trend over the forecast period. The market is driven by technological advancements, the rising prevalence of respiratory disease, and product launches by market players in the North American region.

Bronchoscopy is a generally performed process for diagnostic as well as therapeutic indications. Around 500,000 bronchoscopies are conducted every year in the U.S. Also, in June 2021, the U.S. Food and Drug Administration (FDA) provided updated information about medical device benefits, risks and handling recommendations for healthcare providers on bronchoscopes. This includes the benefits and risks associated with infection of flexible and rigid bronchoscopes while performing bronchoscopy procedures.

In addition, the market players are adopting the market strategies such as acquisition and product launches. For instance, in May 2020, Fujifilm Holdings Corporation announced various global milestones and initiatives to expand its endoscopy and endoscopic health portfolio, which included the addition of artificial intelligence, high-tech image capture and advanced data processing.

Competitive Landscape

The bronchoscope market is a moderately competitive presence of local and global companies. Some of the key players which are contributing to the growth of the market are Olympus Corporation, Cogentix Medical, FUJIFILM Holdings Corporation, Teleflex Incorporated, HOYA Corporation, KARL STORZ GmbH, Ambu A/S, Boston Scientific, EMOS technology, and Richard Wolf GmbH, among others. The major players are adopting several growth strategies, such as product launches, acquisitions, and collaborations, contributing to the growth of the bronchoscope market globally.

For instance,

• In May 2022, Ambu declared that Ambu aScope 5 Broncho, a family of single-use sterile bronchoscopes, has accepted European regulatory clearance. With this launch of aScope 5 Broncho, the company will enter into the Bronchoscopy Suite, an untapped segment of 3 million more procedures where high image quality and handling performance are key and where workflow and patient safety play an important role.

Olympus Corporation

Overview:

Olympus Corporation is a Japanese organization founded in 1931 and headquartered in Tokyo, Japan. The company provides products, including medical systems, life science solutions, and industry solutions. The company offers medical endoscopes, endotherapy devices, and therapeutic energy devices in medical systems.

Product Portfolio:

Diagnostic Bronchoscope (BF-XP190): The ultra-slim design of the BF-XP190 bronchoscope provides small anatomy bronchoscopy with outstanding handling, unmatched image quality, and improved functionality. It offers a high-resolution image, 210° tip angulation and rotary function.

The global bronchoscope market report would provide access to approximately 40+ market data tables, 45+ figures, and in the range of 200 (approximate) pages.